Therapixel recently closed a series B fundraising round worth 15 million euros that will accelerate the commercial deployment of its artificial intelligence (AI) 2D/3D mammography software.
The round was led by Crédit Mutuel Innovation and CapHorn, joined by Verve Ventures, and Sham Innovation Santé, as well as historical investors Omnes, IT-Translation, M-Capital, and Région Sud Investissement.
The company said the funds will push its commercial presence in the U.S., launch more features for its MammoScreen software, and bolster its intelligent reading aid for mammography. MammoScreen has two regulatory clearances in the U.S. from the country's Food and Drug Administration for both 2D and 3D mammography.
